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INTRODUCTION 
 
MEDICINAL CHEMISTRY:- 
             The Medicinal chemistry is the Branch of Science, which study about the synthesis, 
SAR, QSAR, Molecular biology, structure modification for optimization of their activity and 
Biological activity of medicinal compounds. Drug synthesized from natural source by 
Extraction and isolated the lead compounds. Then it is involved in the semi synthetic, synthetic 
process and retro synthetic analysis. 
 Medicinal chemistry gives new strategies in the field of Drug research, it scrutinised the 
physiochemical properties, Drug receptor binding mechanism and computer aided Drug Design 
of medicinal compounds. Recently Drug discovery studies have focused on the design and 
synthesis of small molecules combine to form new drug, it is emphasised in combinatorial 
chemistry. 
 Combinatorial chemistry can be viewed as a tool which allows large number of 
compounds to be synthesised simultaneously in a time taken to prepare only handful 
compounds by traditional Synthetic methods. 
 Medicinal chemistry is one of the most rapidly developing areas within the discipline of 
chemistry both globally and locally.  It is the study of the design, biochemical effects, 
regulatory and ethical aspects of drugs for the treatment of disease. 
   Medicinal chemistry combines to form a set of highly interdisciplinary sciences, setting 
its organic physical and computational emphases alongside biological areas such as 
biochemistry, molecular biology, Pharmacognosy and pharmacology, toxicology and human 
medicine; these with project management, statistics and pharmaceutical business practices, 
systematically oversee altering identified chemical agents such that after pharmaceutical 
formulation, they are safe and efficacious and therefore suitable for use in treatment of disease. 
CHAPTER -I                                                                                    INTRODUCTION 
 
Department of Pharmaceutical Chemistry, MMC, Madurai. 2 
 
 
ISATIN AN OUTLOOK6 
   BASIC NUCLEUS 
N
H
O
O
 
 Isatin or 1H-indole 2, 3 Dione is an indole derivative. The compound was first obtained 
by Eradman and Laurent in 1841 as a product form the oxidation of indigo dye by nitric acid 
and chromic acids. The compound is found in many plants such as Isatistinctoria, 
Calanthediscolor and in Couroupitaquianensis. 
Structural activity relationship (SAR) 
 Bond acceptor at the position 3 
 Free rotation bond O≠ H 
 Bond donar at the position 1 
 Polar surface area 37,38 
 C5, C6 and C7 substitution generally enhanced CNS activity with some 
Di and tri halogenated isatin 
 Isatin [1H-Indole-2,3-dione] an oxidised derivative of indole, was first Discovered by 
Erdmann and laurent in 1840  as a product arising from the oxidation of indigo using nitric acid 
and chromic acid. The compound was considered synthetic for almost 140 years until it was 
found to be present in plants from the Isatis genus, in fruits of the cannon ball tree, couroupita  
guianensis  aubl and in secretion from the parotid gland of the Bufo frog. Various substituted 
isatins have also been identified in plants, fungi, Symbiotic bacteria and marine  molluses. 
Where they are postulated to play a defensive role against pathogenic organism. 
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 In humans and other mammals, isatin is found as an endogenous molecule. Although 
the metabolic pathways of isatin have not yet been fully elucidated, it has been proposed that it 
is synthesised in vivo from tryptophan – rich foods such as meat, dairy and whole grains. In 
this pathway ,tryptophan is converted to indole by bacteria from the gastro intestinal tract and 
then transported to the liver .where it is oxidised. Isatin also plays major role in many 
physiological pathways. 
 Isatin is a versatile chemical building block, able to form a large number of hetero 
cyclic molecules. The compound possesses an indole ring  structure , common to many 
pharmaceuticals, isatin itself possesses an extensive range of biological activities. Isatin is able 
to participate in a broad range of synthetic reactions, leading to extensive use as a precursor 
molecule in  medicinal  chemistry. Here we discuss the potential of isatin and it derivatives to 
create novel bioactive compounds. The basic chemistry and synthesis of isatin derivatives are 
first reviewed. Expanse of  biological, and particularly pharmacological activities of isatin 
compounds are explored. During this discussion, we propose molecular modification to tune 
and refine isatin compounds for use in specific therapies. 
 Isatin and its derivatives are responsible for a broad spectrum of biological activities. 
Among these the cytotoxic and anti neoplastic properties have been the most widely reported. 
The synthetic  versatility of the isatin, due to its privileged scaffold, has led to the generation of 
a large number of structurally diverse derivatives  which include analogues derived from either 
mono, Di, tri substitution of the aryl ring A, and/or those obtained by derivatisation of the  
isatin  nitrogen and C2/C3 carbonyl moieties. These compounds inhibit cancer cell 
proliferation and tumour growth via interaction with a variety of intracellular targets such as 
DNA , telomerase ,  tubulin ,  p-glycoprotien , protein kinases  and phosphatases. Here in we 
review recent highlights in the development of isatin based compounds as anticancer agents 
with a particular focus on the cyto toxicity and structure activity relationship. 
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ANTI OXIDANT11,12 
 
 Anti oxidants are chemical substances that donate their own electron to free radicals 
thus preventing the cellular damages. Anti oxidants are substances that delay or prevent the 
oxidation of cellular oxidizable substrates they exert the effects by scavenging reactive oxygen 
species [ROS] or preventing the generation of [ROS]. 
  Naturally there is balance between the amounts of free radicals produced in the body 
Anti oxidants. The amount of anti oxidants in normal physiological condition is insufficient to 
neutralise free radicals generated in disease or ill condition. Therefore it is obvious to enrich 
our diet with anti oxidant to protect from harmful disease. 
 Oxidative stress is defined in general as excess formulation and are complete removal 
of highly reactive molecule such as oxygen species, singlet oxygen O2* superoxide  
anion [O2¯ ] peroxide radical[RO2] α hydroxyl radical [OH] are through to cause oxidative 
damage .Oxidative stress further leads to ageing process and degenerative disease like cancer, 
inflammation, cardio vascular and  Neurodegenerative disease. 
INVITRO MODELS OF ANTI OXIDANT STUDIES 
1] Conjucated diene assay 
2] DPPH method 
3] Superoxide radical scavenging activity 
4] Hydroxyl radical scavenging activity 
5] Nitric acid radical inhibition assay  
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6] Reducing power method 
7] Phospo molybdenum method 
8] Peroxy nitrile radical scavenging activity 
 9] N,N dimethyl  P- pheylenediamine dihydro chloric method 
10] Oxygen radical absorbance capacity 
11] B-carotene oxidase method 
12] Xanthene oxidase method  
13] Ferric reducing ability of plasma 
14] Total radical trapping antioxidant potential  
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                       ANTI NEOPLASTIC ACTIVITY26,27,28 
 Anti Neo plastic agents are the drugs used in the treatment of cancer, malignancy, 
tumour, carcinoma, sarcoma, leukaemia, etc. Cancer is a class of disease or disorder 
characterized by uncontrolled division of cells and the ability of these to spread either by direct 
growth into adjacent tissue through invasion or by implantation into distant sites by metastasis. 
Two key aspects of cellular life are 
1] DNA synthesis and mitosis to produce new cells 
2] Cell differentiation which Produce specialised cells. 
 Normally cell have control mechanism to moderate these two process by growth factor 
or growth inhibitors A balance between cell growth and cell death is maintained. Cell death is 
actively regulated by process known as apoptosis. Apoptosis is defined as a cell process of cell 
shrinkage, membrane blabbing and nucleus condensation. 
 In cancer cell this regulatory process is aberrant they produce over production of 
growth factor and avoid apoptosis which continue to multiply in an unregulated manner. The 
unregulated growth causes damage to DNA, resulting in mutations to genes that encode from 
protein controlling cell division. 
Cell cycle and regulation  
The cell cycle is divided into four parts 
              1] G1 or Gap 1, 
             2] G2, M and S phase 
            G1—the G1 phase is the period when newly created cell is born 
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             S – Synthesis phase , in this period DNA replicates and two copies of DNA are present      
inthe Cell. 
 G2 – G2 phase and cells are prepared for final cell cycle phase M phase  
  M phase - mitosis or cell division 
             G1/S phase is important in understanding cancer and cancer treatment. 
 The cell cycle is controlled by water soluble protein called growth factor and binds to 
glycoprotein receptors. The growth factor autocrine controls the number of cell in either 
proliferated or non proliferated state and thus maintain homeostatic many cancer cells produce 
excessive level of this growth factor. 
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ANTIBACTERIAL ACTIVITY50 
 
Antibacterial agent:  The drug which inhibit or destroy the growth of bacteria 
 
Organism used for activity:  
 Salmonella Typhi:-  1) Gram negative bacteria 
                                                           2) Motile facultative anaerobe 
                                                           3) Responsible for typhoid 
                                                           4) Possible to control by proper hygiene 
 
          Staphylococcus Aureas:-  1) Gram positive bacteria 
                                                           2) Round shape and golden yellow colour 
                                                           3) Responsible for sinusitis, skin disease 
                                                           4) Possible to control by proper hygiene  
                                           
Mechanism:-Anti Bacterial agent inhibit 
1) Cell wall synthesis 
 
2) Protein synthesis 
 3)   Enzymatic activity 
 4)   Folate metabolism 
 
Evaluation method :-                        1) Turbidimetric method 
  2)  Agar cup plate method 
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LITERATURE REVIEW 
 PANDEYA et al., synthesized Schiff bases of isatin and5-methyl isatin with 
sulphadoxine. The synthesized compounds were tested for antimicrobial activity. 
N
H
O
N SO2NH
N
N
OCH3H3CO
 
 KUMAR et al., synthesized a series of new substituted azetidinoyl and thiazolidinoyl-
1,3,4- thiadiazino (6,5-b) indoles and tested for anti inflammatory activity. 
N
NN
S
NHCH2 S
N N
N
Cl
R
O
 
 AMIR et al., prepared and screened  a series new indole derivatives with anti 
inflammatory activity. 
N
H
N HNH
S
R
 
 RADWAN et al., synthesized and evaluated the analgesic activity of 3-substituted 
indolederivatives.Thethiazolidine -4-one derivatives was found to be exihibit analgesic 
activity. 
N
H
N
S
O
CN
O
Ph
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 PANDEYA et al., synthesized a series of p-nitrophenylsuntitutedsemicarbazone and 
evaluated for anticonvulsant activity. 
N
H
O
R
N N H O
N H
NO 2
 
 LIOU et al.,synthesized and evaluated a series of new indoline-sulfonamide with anti 
cancer activity. 
N
SO 2
OCH 3
N H
O N
 
 
 POPP and PAJOUHESH et al., synthesized 3-o-nitrophenylhydrazones of isatin by 
condensation of isatin with o-nitrophenylhydrazine. These compounds were tested for 
anticancer activity.  
N
H
O
N N H
O 2 N
 
 DUNWANG et al., synthesized some new derivatives of 3-ethoxycarbonyl-6-bromo-5-
hydroxy indole and evaluated for antiviral activity. 
SH 2 C
N
O H
B r
CH 2 NR 3 R 4 .HClH 5 C 2 OOC
R 1  
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 ENIEN et al., synthesized indole-2 and 3-carboxamide and evaluated their biological 
activities as antioxidant activity. 
NO
RNH
X
 
 MISHRA et al., presented a review on natural products as antileishmanial and showed 
the Harmaline is an indole alkaloid as potent leishmanial agent. 
                
N
H
N
H3CO
 
 
 CHAUDHARY et al., showed that various indole derivatives act as effective 
antifertility agents. 
                  
N
R
R 1
R 2
R 3
R 4
 
 Jnyanaranjan Panda et al, reported on the synthesis of Mannich based novel 1, 3-
disubstitued Isatin derivatives of Antibacterial and Antifungal agents. 
                                        
N
O
NH R
N
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 Khalaf Ahmed Jasimet al, submitted the study of some new Mannich bases 
derived from Isatin (1H-indole -2, 3 –Dione) for Antimicrobial activity. 
                                         
N
O
O
R
 
 B. vijaya Kumar et al, reported on the design and synthesis of novel pyridyl –  
2- amidrazone incorporated Isatin Mannich bases for Antimicrobial activity. 
                                          
N
R
O
N + N
N H
N
 
 V. Ravichandranet al, reported on the synthesis of Mannich bases of Isatin and its 
derivatives with 2-[(2, 6 – dichloro phenyl) amino] phenyl acetic acid for 
Antimicrobial activity. 
                                                
N
O
NH R
N
C l
C lHOOC
 
 Sanjay Bari et al, reported on the synthesis of 3-[(5-benzylidene -2-nones for their 
Antimicrobial activity. 
                        
N H
O
NH
N
H
O N
N
O
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 Madhuet al, reported on the synthesis of [3-hydrazono -1, 3- dihydro – 2H – indole 
-2-one] for their Antimicrobial activity. 
                                     
N
H
O
N N H 2
 
 Dhananjay More et al, reported on the synthesis of 1,4 – benzothiazine compound 
containing Isatin moieties as Antimicrobial agent. 
                                   
N
O
N
H
S
O
CH 3
R
 
 Yifeng Sun et al, reported on the synthesis and crystal structure of isatin -3- 
isonicotinoyl hydrazine as Antibacterial agent. 
 
 
 
 Jnyanaranjan Panda et al, reported for efficient synthesis of Isatin derivatives and 
evaluation of their Antibacterial activities. 
                                                
N
H
O
NH R
 
 
N
H
N
NH
O
NO
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 Ramachandran.S et al, reported on the synthesis of Mannich based novel 1, 3, 5 
trisubstituedIsatin derivatives for Analgesic and Ulcerogenic evaluation. 
                           
N
O
N
R
N R 1
N
N
O
O H
F
 
 Nadeem Siddiqui et al, synthesized novel 3, 5 – disubstituedIsatin derivatives of 
Anticonvulsant activity. 
                                                           
N
H
O
N R2
R1
 
 SurendraNathPandeyaet al, reported on the synthesis and Anticonvulsant activity 
of substituted Isatin -3-oximes. 
                                                        
N
O
N O H
RR
2
R 1
 
 Vinit Raj et al, review on Anticonvulsant activity of Isatin derivatives. 
                                 
N
H
N
N
O H
O H
OCH 3
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 Chinnasamy  Rajaram Prakash et al, reported on the synthesis characterization 
and Anticonvulsant activity of novel Schiff base Isatin derivatives. 
                                      
N
H
O
NH N
R
 
 Mostafa.A.Husseinet al, synthesized some Mannich bases derived from 
Isatinisonicotinic acid hydrazone for Antitubercular activity. 
                                         
N
O
N N H CO N
NR 2  
 Venkateshwar Rao et al, reported on the synthesis of isatin -3- [N2- 
(2-benzalamino thiazol-4-yl)] hydrazine for their Anti-inflammatory activity. 
                                       
N
H
O
N N H
S
N
N
R 1
R 2
 
 TarekAboul – Fadlet al, synthesized methisazone plays an important role as 
prophylactic agent against several viral diseases 
 A.W.Galston et al, reported on the synthesis of oxindole -3- acetic acid for auxin 
activity. 
                                                   
N
H
O
COOH
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 Ratnamala.P.Sonawaneet al, reported on the synthesis and spectral studies of 
substituted 5- Nitro-1H-indole-2, 3-dione. 
                                                   
N
H
O
O
O 2 N
 
 JiroTatsugi et al, reported on improved preparation of Isatin for indoles. 
                
              
N
H
O
O
CH 3
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AIM AND OBJECTIVES8,10 
 Isatin and its derivatives are responsible for a broad spectrum of biological activities. 
Already many of the scientist has done the cytotoxicity studies from isatin derivatives. Which 
is substituted by various molecule in the position of isatin certain nitrogen atom,C2,C3 
carbonyl moieties and mono, Di, tri substitution of aryl ring A. 
   In this way I would like to substitution the various aromatic secondary amine  in the 
position of isatin containing nitrogen by mannich reaction and also I have tried with various 
aldehyde instead of formaldehyde for the cytotoxicity  studies and anti bacterial studies. 
Cytotoxicity studies are carried out through cervical cancer cell line.Anti bacterial activities are 
studies through cup- plate method. Anti oxidant properties are studied by hydrogen peroxide 
method. 
 OBJECTIVES: 
            To  synthesis  isatin derivatives by mannich reaction by using stirring method.   It is 
synthesized by two steps . 
a) Isatin synthesis from  aniline with chloral hydrate  by sandmayer reaction. 
b) Isatin react with various aromatic secondary amine like  piperzine, Diphenyl amine, 
pyrolidine, benzimidale by mannich reaction. 
 The synthesized novel series of isatin derivatives were characterized by thin layer 
chromatography and spectral studies like NMR, MASS, IR spectroscopy. 
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Isatin derivatives are designed by following software1 
a) CHEMDOODLE 
b) MOLNSPIRATION 
c) CHEM SKETCH 
Biological evaluation of isatin derivatives  
a) Invitro studies of anti oxidant properties  
b) Invitro studies of anti bacterial activity 
c) Invitro  cytotoxicity studies against cervical cancer cell line. 
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SCHEME OF REACTION 
 
SCHEME :  1 
 
NH2
+
OH
OH
CCl3
+ Na2SO4
N
H
O
O
Sandmayer reaction
NH2OH, HCl
H2SO4
aniline
1H-indole-2,3-dione
 
 
 
 
 
 
 
 
 
 
Chloral Hydrate 
Sodium Sulphate 
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SCHEME : 2 
 
 
N
H
O
O +
HCHO +
N
O
O
NH
R
1H-indole-2,3-dione
Formaldehyde
mannich reaction Ethanol
R -NH
PRODUCT
Secondary amine
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EXPERIMENTAL PROCEDURE 
 STEP 1 
                                 Synthesis of -1H-indole-2,3-dione(isatin) 
Chemicals required: 
 Chloral hydrate 
 Aniline 
 Sodium sulfate  
 Concentrated hydrochloric acid 
 Hydroxylamine hydrochloride 
 Water 
Procedure: 
 Dissolve chloral hydrate, sodium sulfate and aniline in water.  To this add concentrated 
hydrochloric acid and hydroxylamine hydrochloride and heated on a water bath for about 40-
50 minutes. The dried sample is obtained to this add warm concentrated sulphuric acid and 
stirred it in a temperature between 60-70c. until the reaction get completed.  Then it is cooled 
and washed with cold water and dried in air. 
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Synthesis of 1H-indole-2,3-dione 
 
 
          
NH2
+
OH
OH
CCl3
+ Na2SO4
N
H
O
O
Sandmayer reaction
NH2OH, HCl
H2SO4
aniline
1H-indole-2,3-dione
 
 
 
 
 
 
 
Chloral Hydrate 
Sodium Sulphate 
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COMPOUND S1 
Synthesis of 1(piperazine-1-ylmethyl)-1H –indole-2,3 dione 
   Chemicals required: 
 Isatin   -2mmol 
 Piperazine -2mmol 
 Formaldehyde -3mmol 
 Ethanol -10ml 
 Water  -10ml 
 Procedure: 
 Isatin (2mmol) was dissolved in 20ml of ethanol water (1:1) solution and formaldehyde 
37% (3mmol) and add Piperazine (2mmol).  The mixture was stirred at room temperature and 
the reaction was controlled by TLC in benzene: Methanol (9:1) at the end of reaction the 
precipitate was filtered dried and crystallized by using an appropriate solvent. 
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COMPOUND  S1 
Synthesis of 1(piperazine-1-ylmethyl)-1H –indole-2,3 dione 
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                                                         COMPOUND S2 
                Synthesis of 1-(phenyl(piperazine-1-yl)-H-indole-2,3 dione 
           Chemicals required: 
 Isatin   -2mmol 
 Piperazine -2mmol 
 Benzaldehyde -3mmol 
 Ethanol -10ml 
 Water  -10ml 
 
Procedure: 
 Isatin (2mmol) was dissolved in 20ml of ethanol water (1:1) solution and  benzaldehyde 
(3mmol) and add Piperazine (2mmol).  The mixture was stirred at room temperature and the 
reaction was controlled by TLC in benzene.  Methanol (9:1) at the end of reaction the 
precipitate was filtered dried and crystallized by using an appropriate solvent. 
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COMPOUND S2 
                Synthesis of 1-(phenyl(piperazine-1-yl)-H-indole-2,3 dione 
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COMPOUND S3 
Synthesis of 1-[(4 chlorophenyl)piperazine-1-yl methyl]-1H-indole-2, 3 –dione 
Chemicals required: 
 Isatin    -2mmol 
 Piperazine  -2mmol 
 P-chloro Benzaldehyde-3mmol 
 Ethanol  -10ml 
 Water   -10ml 
 Procedure: 
 Isatin (2mmol) was dissolved in 20ml of ethanol water (1:1) solution and 4-chloro 
Benzaldehyde (3mmol) and add piperazine (2mmol).  The mixture was stirred at room 
temperature and the reaction was controlled by TLC in benzene:Methanol (9:1) at the end of 
reaction the precipitate was filtered dried and crystallized by using an appropriate solvent. 
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COMPOUND S3 
Synthesis of 1-[(4 chlorophenyl)piperazine-1-yl methyl]-1H-indole-2, 3 –dione 
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COMPOUND S4 
Synthesis of 1-[ (4 –dimethyl amino) (Piperazine-1-yl methyl]-1H-indole-2, 3 –dione 
Chemicals required: 
 Isatin      -2mmol 
 Piperazine    -2mmol 
 P- dimethyl amino benzaldehyde -3mmol 
 Ethanol    -10ml 
 Water     -10ml 
Procedure: 
 Isatin (2mmol) was dissolved in 20ml of ethanol water (1:1) solution and p-dimethyl 
amino benzaldehyde (3mmol) and add piperazine (2mmol). The mixture was stirred at room 
temperature and the reaction was controlled by TLC in benzene: Methanol (9:1) at the end of 
reaction the precipitate was filtered dried and crystallized by using an appropriate solvent. 
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COMPOUND S4 
Synthesis of 1-[ (4 –dimethyl amino) (Piperazine-1-yl methyl]-1H-indole-2, 3 –dione 
 
1-[ (4 –dimethyl amino) (Piperazine-1-yl methyl]-1H-indole-2, 3 –dione 
 
 
  
CHAPTER - V                                                             EXPERIMENTAL PROCEDURE 
 
Department of Pharmaceutical Chemistry, MMC, Madurai. 31 
 
 
 
COMPOUND S5 
Synthesis of 1-[(4 methoxy phenyl)(Piperazine-1-yl methyl]-1H-indole-2, 3 –dione 
Chemicals required: 
 Isatin   -2mmol 
 Piperazine -2mmol 
 Anisaldehyde -3mmol 
 Ethanol -10ml 
 Water  -10ml 
Procedure: 
 Isatin (2mmol) was dissolved in 20ml of ethanol water (1:1) solution and  anisaldehyde 
(3mmol) and add piperazine (2mmol).  The mixture was stirred at room temperature and the 
reaction was controlled by TLC in benzene.  Methanol (9:1) at the end of reaction the 
precipitate was filtered dried and crystallized by using an appropriate solvent. 
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COMPOUND S5 
Synthesis of 1-[(4 methoxy phenyl)(Piperazine-1-yl methyl]-1H-indole-2, 3 –dione 
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                                                             COMPOUND S6 
                   Synthesis of 1-[diphenyl amine- yl- methyl]-1H-indole-2, 3 –dione 
   Chemicals required: 
 Isatin   -2mmol 
 diphenylamine -2mmol 
 Formaldehyde -3mmol 
 Ethanol -10ml 
 Water  -10ml 
   Procedure: 
 Isatin (2mmol) was dissolved in 20ml of ethanol water (1:1) solution and formaldehyde 
37% (3mmol) and add diphenylamine (2mmol).  The mixture was stirred at room temperature 
and the reaction was controlled by TLC in benzene: Methanol (9:1) at the end of reaction the 
precipitate was filtered dried and crystallized by using an appropriate solvent. 
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COMPOUND S6 
                   Synthesis of 1-[diphenyl amine- yl- methyl]-1H-indole-2, 3 –dione 
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COMPOUND S7 
       Synthesis of 1-[Diphenylamine,phenyl-1-yl methyl]-1H-indole-2, 3 –dione 
 
Chemicals required: 
 Isatin   -2mmol 
 Diphenylamine-2mmol 
 Benzaldehyde -3mmol 
 Ethanol -10ml 
 Water  -10ml 
Procedure: 
 Isatin (2mmol) was dissolved in 20ml of ethanol water (1:1) solution and Benzaldehyde 
(3mmol) and add Dyphenylamine (2mmol).  The mixture was stirred at room temperature and 
the reaction was controlled by TLC in benzene.  Methanol (9:1) at the end of reaction the 
precipitate was filtered dried and crystallized by using an appropriate solvent. 
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COMPOUND S7 
       Synthesis of 1-[Diphenylamine,phenyl-1-yl methyl]-1H-indole-2, 3 –dione 
 
1-[Diphenylamine,phenyl-1-yl methyl]-1H-indole-2, 3 –dione 
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COMPOUND S8 
Synthesis of 1-[1H-benzimidazole-1-yl methyl]-1H-indole-2, 3 –dione 
Chemicals required: 
 Isatin   -2mmol 
 Benzimidazole-2mmol 
 Formaldehyde -3mmol 
 Ethanol -10ml 
 Water  -10ml 
Procedure: 
 Isatin (2mmol) was dissolved in 20ml of ethanol water (1:1) solution and formaldehyde 
37% (3mmol) and add Benzimidazole (2mmol).  The mixture was stirred at room temperature 
and the reaction was controlled by TLC in benzene.  Methanol (9:1) at the end of reaction the 
precipitate was filtered dried and crystallized by using an appropriate solvent. 
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COMPOUND S8 
Synthesis of 1-[1H-benzimidazole-1-yl methyl]-1H-indole-2, 3 –dione 
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                                                              COMPOUND S9 
                Synthesis of 1-(pyrrolidine-1-yl methyl) -1H –indole-2,3 dione 
Chemicals required: 
 Isatin   -2mmol 
 Pyrrolidine -2mmol 
 Formaldehyde -3mmol 
 Ethanol -10ml 
 Water  -10ml 
Procedure: 
 Isatin (2mmol) was dissolved in 20ml of ethanol water (1:1) solution and formaldehyde 
37% (3mmol) and add pyrrolidine (2mmol).  The mixture was stirred at room temperature and 
the reaction was controlled by TLC in benzene.  Methanol (9:1) at the end of reaction the 
precipitate was filtered dried and crystallized by using an appropriate solvent. 
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COMPOUND S9 
                            Synthesis of1-(pyrrolidine-1-yl methyl) -1H –indole-2,3 dione 
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COMPOUND  S10 
 
Synthesis of  3-(Piperazine-1-yl methyl)-1H-indole 
   Chemicals required: 
 Indole   -2mmol 
 Piperazine -2mmol 
 Formaldehyde -3mmol 
 Ethanol -10ml 
 Water  -10ml 
    Procedure: 
 Indole (2mmol) was dissolved in 20ml of ethanol water (1:1) solution and 
formaldehyde 37% (3mmol) and add piperazine (2mmol).  The mixture was stirred at room 
temperature and the reaction was controlled by TLC in benzene.  Methanol (9:1) at the end of 
reaction the precipitate was filtered dried and crystallized by using an appropriate solvent. 
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COMPOUND  S10 
 
Synthesis of  3-(Piperazine-1-yl methyl)-1H-indole 
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MOLECULAR DESIGN 
 
COMPOUND S1 
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COMPOUND S2 
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COMPOUND S3 
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COMPOUND S4 
 
1-[ (4 –dimethyl amino) (Piperazine-1-yl methyl]-1H-indole-2, 3 –dione 
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COMPOUND S5 
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COMPOUND S6 
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COMPOUND S7 
 
1-[Diphenylamine,phenyl-1-yl methyl]-1H-indole-2, 3 –dione 
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COMPOUND S8 
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COMPOUND S9 
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COMPOUND S10 
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1(piperazine-1-ylmethyl)-1H –indole-2,3 dione 
S1 
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1-(phenyl(piperazine-1-yl)-H-indole-2,3 dione 
S2 
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1-[(4 chlorophenyl)piperazine-1-yl methyl]-1H-indole-2, 3 –dione 
 
S3 
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1-[ (4 –dimethyl amino) (Piperazine-1-yl methyl]-1H-indole-2, 3 –dione 
 
 
S4 
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1-[(4 methoxy phenyl)(Piperazine-1-yl methyl]-1H-indole-2, 3 –dione 
 
S5 
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1-[diphenyl amine- yl- methyl]-1H-indole-2, 3 –dione 
 
S6 
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1-[Diphenylamine,phenyl-1-yl methyl]-1H-indole-2, 3 –dione 
 
S7 
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1-[1H-benzimidazole-1-yl methyl]-1H-indole-2, 3 –dione 
 
S8 
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1-(pyrrolidine-1-yl methyl) -1H –indole-2,3 dione 
 
 
S9 
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3-(Piperazine-1-yl methyl)-1H-indole 
 
S10 
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MOLINSPIRATION 
 
S1 
 
Molinspiration property engine v2013.09 
 
miLogP         0.211 
TPSA           54.341 
natoms         18.0 
MW             245.282 
nON            5 
nOHNH          1 
nviolations    0 
nrotb          2 
volume         222.30 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.40 
Ion channel modulator      -0.66 
Kinase inhibitor           -0.34 
Nuclear receptor ligand    -1.23 
Protease inhibitor         -0.66 
Enzyme inhibitor           -0.05 
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S2 
 
Molinspiration property engine v2013.09 
 
miLogP         1.793 
TPSA           54.341 
natoms         24.0 
MW             321.38 
nON            5 
nOHNH          1 
nviolations    0 
nrotb          3 
volume         293.741 
 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.11 
Ion channel modulator      -0.39 
Kinase inhibitor           -0.16 
Nuclear receptor ligand    -0.55 
Protease inhibitor         -0.08 
Enzymeinhibitor            -0.14 
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S3 
 
 
 
Molinspiration property engine v2013.09 
 
miLogP         2.471 
TPSA           54.341 
natoms         25.0 
MW             355.825 
nON            5 
nOHNH          1 
nviolations    0 
nrotb          3 
volume         307.276 
 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.11 
Ion channel modulator      -0.38 
Kinase inhibitor           -0.18 
Nuclear receptor ligand    -0.55 
Protease inhibitor         -0.12 
Enzyme inhibitor           -0.17 
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S4 
 
 
Molinspiration property engine v2013.09 
 
miLogP         1.895 
TPSA           57.579 
natoms         27.0 
MW             364.449 
nON            6 
nOHNH          1 
nviolations    0 
nrotb          4 
volume         339.647 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.10 
Ion channel modulator      -0.37 
Kinase inhibitor           -0.12 
Nuclear receptor ligand    -0.48 
Protease inhibitor         -0.10 
Enzymeinhibitor           -0.15 
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S5 
 
 
Molinspiration property engine v2013.09 
 
miLogP         1.85 
TPSA           63.575 
natoms         26.0 
MW             351.406 
nON            6 
nOHNH          1 
nviolations    0 
nrotb          4 
volume         319.286 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.15 
Ion channel modulator      -0.43 
Kinase inhibitor           -0.19 
Nuclear receptor ligand    -0.52 
Protease inhibitor         -0.13 
Enzymeinhibitor           -0.18 
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S6 
 
Molinspiration property engine v2013.09 
 
miLogP         4.31 
TPSA           42.314 
natoms         25.0 
MW             328.371 
nON            4 
nOHNH          0 
nviolations    0 
nrotb          4 
volume         296.356 
 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.11 
Ion channel modulator      -0.35 
Kinase inhibitor           -0.07 
Nuclear receptor ligand    -0.42 
Protease inhibitor         -0.19 
Enzymeinhibitor            0.03 
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S7 
 
 
Molinspiration property engine v2013.09 
 
miLogP         5.891 
TPSA           42.314 
natoms         31.0 
MW             404.469 
nON            4 
nOHNH          0 
nviolations    1 
nrotb          5 
volume         367.79 
 
 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.14 
Ion channel modulator      -0.35 
Kinase inhibitor           -0.14 
Nuclear receptor ligand    -0.34 
Protease inhibitor         -0.15 
Enzymeinhibitor           -0.11 
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S8 
 
 
 
Molinspiration property engine v2013.09 
 
miLogP         2.07 
TPSA           56.902 
natoms         21.0 
MW             277.283 
nON            5 
nOHNH          0 
nviolations    0 
nrotb          2 
volume         237.366 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.01 
Ion channel modulator      -0.30 
Kinase inhibitor            0.02 
Nuclear receptor ligand    -0.46 
Protease inhibitor         -0.12 
Enzymeinhibitor            0.08 
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S9 
 
Molinspiration property engine v2013.09 
 
miLogP         1.318 
TPSA           42.314 
natoms         17.0 
MW             230.267 
nON            4 
nOHNH          0 
nviolations    0 
nrotb          2 
volume         209.904 
Molinspiration bioactivity score v2011.06 
GPCR ligand                -0.54 
Ion channel modulator      -0.69 
Kinase inhibitor           -0.52 
Nuclear receptor ligand    -1.18 
Protease inhibitor         -0.68 
Enzymeinhibitor           -0.06 
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S10 
 
 
Molinspiration property engine v2013.09 
 
miLogP         1.188 
TPSA           31.056 
natoms         16.0 
MW             215.3 
nON            3 
nOHNH          2 
nviolations    0 
nrotb          2 
volume         211.374 
 
Molinspiration bioactivity score v2011.06 
GPCR ligand                 0.20 
Ion channel modulator       0.25 
Kinase inhibitor            0.11 
Nuclear receptor ligand    -0.54 
Protease inhibitor         -0.28 
Enzymeinhibitor            0.09 
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ANALYTICAL TECHNICHE 
 
IR SPECTROSCOPY49 
 Infrared spectroscopy or vibrational spectroscopy is concerned with the study of 
absorption of infrared radiation, which results in vibrational transition. IR spectra is mainly 
used in structure elucidation to determine the functional group. 
Principle: 
               In any molecule, It is known that atoms or groups of atoms one connected by bonds. 
These bonds are analogues to springs and not rigid in nature. Because of the continuous 
motion of the molecule. They maintain some vibrations with some frequency. Characteristic to 
every portion of the molecule. This is called the natural frequency of vibration. 
                When energy in the form of infrared radiation is applied and when every bond or 
portion of a molecule or functional group requires different frequency for absorption. Hence 
characteristic  peak is observed for every functional group or part of the molecule. In other 
words IR structure is Nothing but a finger print of a molecule. (Main application of IR spectra 
is identification of functional group and structure elucidation.) 
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NUCLEAR MAGNETIC RESONANCE25,26 
   The NMR spectroscopy depends upon the fact that most isotopes of the elements 
posses  gyromagnetic properties, meaning thereby that they behave like tiny spinning bar 
magnets.  When a sample containing nuclei exhibiting this immutable  gyromagnetism  is 
placed in an appropriate  DC Magnetic field and is simultaneously irradiated by weaker 
rotating radio frequency  magnetic field the nuclei can be compelled to  
A]  Reveal their presence 
B] Identify themselves and 
C] Describe the nature of their  surroundings 
 All by means of minute radiological which they transmit to a receiver coil coupled 
closely to the sample. 
PRINCIPLE: 
            NMR involves the interaction between an oscillating magnetic field of electromagnetic 
radiation and the magnetic energy of the H nucleus when these are placed in an external static 
magnetic field. 
 The sample absorbs electromagnetic radiation in radiowave region at different 
frequency since absorption depends upon the type of protons or certain nuclei contained in the 
sample consider a spinning top. 
          It performs a slower waltz like motion in which the spinning axis of the topmoves 
slowly around the vertical axis. This is precessional motion and the top is said to be precessing 
around the vertical axis of the earth gravitational field. 
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          The precession arise from the interaction of spin with earth gravity acting vertically 
downloads. It is known gyroscopic motion. 
         NMR spectroscopy is the study of spin changes at the nucleus level. When a radio 
frequency energy is absorbed in the presence of magnetic field. When proton (hydrogen) is 
studied then its called as proton magnetic resonance (PMR). When other nuclei like C13, 19F, 
35Cl etc is studied then it is called as NMR. 
 Generally in practice the study of hydrogen. Itself is called as NMR spectra. Nuclei 
with odd mass number only give NMR spectra eg. 1H, 13C, 19F, 35Cl etc. Because they have 
assymetrical charge distribution. 
COMPLICATION IN NMR ANALYSIS 
1. Hydrogen bonding  
2. Overlapping 
3. Solvent effects. 
4. Exchange of proton. 
LIMITATION IN NMR STUDIES: 
• Lack of sensitivity. 
• Choice of solvent is restricted. 
• Fairly large samples are required minimum sample size is 0.1ml having minimum  
• concentration about 1%. 
• Limited number of nuclei may be studied. 
• In some compounds, two different type of hydrogen atom resonate at some resonancd 
frequencies .theis result in an overlap of spectra and make such spectra difficult to 
interpret. 
• In most of the cases, only liquid can be studied by NMR spectroscopy. 
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APPLICATION: 
• Structural Diagnoses. 
• Complex spectra can be simplified by deuterium labelling. 
• Identification of structural isomers. 
• Conformational analysis. 
• Distinction between cis and trans isomers. 
• Detection of hydrogen bonding. 
• Detection of electro negative atom. 
• Detection of aromaticity. 
• Keto-enoltautomerism. 
• Elemental analysis 
• Detection of Double bond Character. 
• Quantitative analysis. 
 
MASS SPECTROSCOPY26 
 Mass or molecules weight of a compound can be found in several ways. One such 
technique is using mass spectrometer not only for determination of mass.  But the technique 
can be used for structure elucidation, quantitative analysis and even advanced studies could be 
done by using mass spectrum of a compound. 
 
 
CHAPTER - VII                                                             SPECTRAL DATA 
 
Department of Pharmaceutical Chemistry, MMC, Madurai. 77 
 
 
Basic principle: 
               Mass spectroscopy is the most accurate method for determining the molecular mass 
of the compounds and its elemental composition. In this technique, the compound under 
investigation is bombarded with a beam of energetic electrons. The molecules are ionised and 
dissociate with several fragments, some of which are positive ions each kind of ions have a 
particular ratio of mass to change ie m/e ratio. 
 Mass spectra is called as positive ion spectra or ion spectra unlike other kinds of 
spectroscopy we don’t use any electromagnetic radiation [EMR] we use electron 
bombardment to convert a neutral molecule to positive charged one also there is no ground or 
excited state  like other type of spectroscopy mass spectroscopy is not a true spectroscopic 
technique  because of absorption of electromagnet energy is not involved in any way. The 
important advantages of mass spectroscopy are its high sensitivity, reproducibility, accuracy 
and the amount sample required for mass spectral analysis material present in concentration 
less than 1 ppm can be easily detected by this technique . 
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                                               IR SPECTROSCOPY 
COMPOUND  S1 
 
 
 
 
COMPOUND   S2 
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COMPOUND S3 
 
 
 
 
  COMPOUND  S4 
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COMPOUND  S5 
 
 
 
 
COMPOUND   S6 
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COMPOUND   S7 
 
 
 
COMPOUND  S8 
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COMPOUND  S9 
 
 
 
COMPOUND S10 
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                                            NMR SPECTROSCOPY 
 
S1, 
          Current Data Parameters 
              NAME   Feb10−2014 
              EXPNO   9 
              PROCNO  1 
              F2 − Acquisition Parameters 
              Date_   20140210 
              Time   22.03 
              INSTRUM  spect 
              PROBHD  5 mm PABBO BB− 
              PULPROG zg30 
              TD   32768 
              SOLVENT  DMSO 
              NS   32 
              DS   2 
              SWH   10330.578 Hz 
              FIDRES   0.315264 Hz 
              AQ  1.5860212 sec 
              RG   203 
              DW   48.400 usec 
              DE   6.50 usec 
              TE   300.1 K 
              D1 1.00000000 sec 
              TD0   1 
              ======== CHANNEL f1 ======== 
              NUC1   1H 
              P1   10.65 usec 
              PL1   0.00 dB 
              PL1W   23.53637505 W 
              SFO1  500.1330885 MHz 
              F2 − Processing parameters 
              SI   32768 
              SF 500.1300039 MHz 
              WDW   EM 
              SSB   0 
              LB   0.30 Hz 
              GB   0 
              PC   1.00 
13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm    
    4.
31
 
2.2
75
.
57
3.1
92
.
81
3.0
31
.01
 
1 . 0 0     2.
1
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S2,  
          Current Data Parameters 
              NAME   Feb10- 2014 
              EXPNO   4 
              PROCNO  1 
              F2 -  Acquisition Parameters 
              Date_   201402610 
              Time   21.46 
              INSTRUM  spect 
              PROBHD  5 mm PABBO BB-  
              PULPROG zg30 
              TD   32768 
              SOLVENT  DMSO 
              NS   32 
              DS   2 
              SWH   10330.578 Hz 
              FIDRES   0.315264 Hz 
              AQ  1.5860212 sec 
              RG   203 
              DW   48.400 usec 
              DE   6.50 usec 
              TE   300.1 K 
              D1 1.00000000 sec 
              TD0   1 
              ======== CHANNEL f1 ======== 
              NUC1   1H 
              P1   10.65 usec 
              PL1   0.00 dB 
              PL1W   23.53637505 W 
              SFO1  500.1330885 MHz 
              F2 -  Processing parameters 
              SI   32768 
              SF 500.1300000 MHz 
              WDW   EM 
              SSB   0 
              LB   0.30 Hz 
              GB   0 
              PC   1.00 
13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm    
    0.
30
 
3.2
00.7
84
.51
1.3
41.
272
.04
1.0
0 
 0.
47
 
  2.
39
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S3, 
          Current Data Parameters 
              NAME   Feb10−2014 
              EXPNO   26 
              PROCNO  1 
              F2 − Acquisition Parameters 
              Date_   20140210 
              Time   4.47 
              INSTRUM  spect 
              PROBHD  5 mm PABBO BB− 
              PULPROG zg30 
              TD   32768 
              SOLVENT  DMSO 
              NS   32 
              DS   2 
              SWH   10330.578 Hz 
              FIDRES   0.315264 Hz 
              AQ  1.5860212 sec 
              RG   203 
              DW   48.400 usec 
              DE   6.50 usec 
              TE   299.2 K 
              D1 1.00000000 sec 
              TD0   1 
              ======== CHANNEL f1 ======== 
              NUC1   1H 
              P1   10.65 usec 
              PL1   0.00 dB 
              PL1W   23.53637505 W 
              SFO1  500.1330885 MHz 
              F2 − Processing parameters 
              SI   32768 
              SF 500.1300036 MHz 
              WDW   EM 
              SSB   0 
              LB   0.30 Hz 
              GB   0 
              PC   1.00 
13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm    
      1.
00
 
1. 07
 
1.
1
3          
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S4, 
           Current Data Parameters 
               NAME   Feb10−2014 
               EXPNO   13 
               PROCNO  1 
               F2 − Acquisition Parameters 
               Date_   20140210 
               Time   22.17 
               INSTRUM  spect 
               PROBHD  5 mm PABBO BB− 
               PULPROG zg30 
               TD   32768 
               SOLVENT  DMSO 
               NS   32 
               DS   2 
               SWH   10330.578 Hz 
               FIDRES   0.315264 Hz 
               AQ  1.5860212 sec 
               RG   203 
               DW   48.400 usec 
               DE   6.50 usec 
               TE   300.1 K 
               D1 1.00000000 sec 
               TD0   1 
               ======== CHANNEL f1 ======== 
               NUC1   1H 
               P1   10.65 usec 
               PL1   0.00 dB 
               PL1W   23.53637505 W 
               SFO1  500.1330885 MHz 
               F2 − Processing parameters 
               SI   32768 
               SF 500.1300042 MHz 
               WDW   EM 
               SSB   0 
               LB   0.30 Hz 
               GB   0 
               PC   1.00 
13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm    
    0.
45
 
 0.9
75
.
56
 
5.
85
 
 6.
1
0 
0 1 . 5 6
6.
0
1        
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S5, 
           Current Data Parameters 
               NAME   Feb10−2014 
               EXPNO   12 
               PROCNO  1 
               F2 − Acquisition Parameters 
               Date_   20140210 
               Time   22.13 
               INSTRUM  spect 
               PROBHD  5 mm PABBO BB− 
               PULPROG zg30 
               TD   32768 
               SOLVENT  DMSO 
               NS   32 
               DS   2 
               SWH   10330.578 Hz 
               FIDRES   0.315264 Hz 
               AQ  1.5860212 sec 
               RG   203 
               DW   48.400 usec 
               DE   6.50 usec 
               TE   300.1 K 
               D1 1.00000000 sec 
               TD0   1 
               ======== CHANNEL f1 ======== 
               NUC1   1H 
               P1   10.65 usec 
               PL1   0.00 dB 
               PL1W   23.53637505 W 
               SFO1  500.1330885 MHz 
               F2 − Processing parameters 
               SI   32768 
               SF 500.1300000 MHz 
               WDW   EM 
               SSB   0 
               LB   0.30 Hz 
               GB   0 
               PC   1.00 
13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm    
   1.
0
0  0.
95
 
1.
97
 
2.
00
 
   2. 66
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S6, 
          Current Data Parameters 
               NAME   Feb10−2014 
               EXPNO   25 
               PROCNO  1 
               F2 − Acquisition Parameters 
               Date_   20140210 
               Time   4.43 
               INSTRUM  spect 
               PROBHD  5 mm PABBO BB− 
               PULPROG zg30 
               TD   32768 
               SOLVENT  DMSO 
               NS   32 
               DS   2 
               SWH   10330.578 Hz 
               FIDRES   0.315264 Hz 
               AQ  1.5860212 sec 
               RG   181 
               DW   48.400 usec 
               DE   6.50 usec 
               TE   299.3 K 
               D1 1.00000000 sec 
               TD0   1 
               ======== CHANNEL f1 ======== 
               NUC1   1H 
               P1   10.65 usec 
               PL1   0.00 dB 
               PL1W   23.53637505 W 
               SFO1  500.1330885 MHz 
               F2 − Processing parameters 
               SI   32768 
               SF 500.1300000 MHz 
               WDW   EM 
               SSB   0 
               LB   0.30 Hz 
               GB   0 
               PC   1.00 
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm    
  0 . 8 9    
1.
8
4 
1.
90
 
  3.
00
 
0.
7
8        
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S7, 
          Current Data Parameters 
              NAME   Feb10−2014 
              EXPNO   7 
              PROCNO  1 
              F2 − Acquisition Parameters 
              Date_   20140210 
              Time   21.56 
              INSTRUM  spect 
              PROBHD  5 mm PABBO BB− 
              PULPROG zg30 
              TD   32768 
              SOLVENT  DMSO 
              NS   32 
              DS   2 
              SWH   10330.578 Hz 
              FIDRES   0.315264 Hz 
              AQ  1.5860212 sec 
              RG   161 
              DW   48.400 usec 
              DE   6.50 usec 
              TE   300.1 K 
              D1 1.00000000 sec 
              TD0   1 
              ======== CHANNEL f1 ======== 
              NUC1   1H 
              P1   10.65 usec 
              PL1   0.00 dB 
              PL1W   23.53637505 W 
              SFO1  500.1330885 MHz 
              F2 − Processing parameters 
              SI   32768 
              SF 500.1300039 MHz 
              WDW   EM 
              SSB   0 
              LB   0.30 Hz 
              GB   0 
              PC   1.00 
13 12 11 10 9 8 7 6 5 4 3 2 1 0 ppm    
   1.
0
5   1.9
5
1.9
9 
    3.
00
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S8, 
            Current Data Parameters 
                NAME   Feb10−2014 
                EXPNO   2 
                PROCNO  1 
                F2 − Acquisition Parameters 
                Date_   20140210 
                Time   21.39 
                INSTRUM  spect 
                PROBHD  5 mm PABBO BB− 
                PULPROG zg30 
                TD   32768 
                SOLVENT  DMSO 
                NS   32 
                DS   2 
                SWH   10330.578 Hz 
                FIDRES   0.315264 Hz 
                AQ  1.5860212 sec 
                RG   181 
                DW   48.400 usec 
                DE   6.50 usec 
                TE   299.9 K 
                D1 1.00000000 sec 
                TD0   1 
                ======== CHANNEL f1 ======== 
                NUC1   1H 
                P1   10.65 usec 
                PL1   0.00 dB 
                PL1W   23.53637505 W 
                SFO1  500.1330885 MHz 
                F2 − Processing parameters 
                SI   32768 
                SF 500.1300000 MHz 
                WDW   EM 
                SSB   0 
                LB   0.30 Hz 
                GB   0 
                PC   1.00 
13 12 11 10 9 8   7 6 5 4 3 2 1 0 ppm    
     2.
54
 
1.
22
 
6.
35
 
4.
38
 
1. 00
 
 19
.
91
 
        
 
CHAPTER - VII                                                             SPECTRAL DATA 
 
Department of Pharmaceutical Chemistry, MMC, Madurai. 91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
S 9 ,  C u r r e n t D a ta  P a r a m e te r s  
 N A M E    F e b 1 0 - 2 0 1 4  
 E X P N O    20 
 P R O C N O   1  
 F 2  -  A c q uis i t ion  P a r a m e te rs  
 D a t e _    2 0 1 4 0 2 1 0  
 T im e    1 3 . 2 6  
 IN S T R U M   s p e c t 
 P R O B H D   5  m m  P A B B O  B B -  
 P U LP R O G  zg 3 0  
 T D    3 2 7 6 8  
 S O L V E N T   D M S O  
 N S    3 2  
 D S    2  
 S W H    1 0 3 3 0 .5 7 8  H z  
 F ID R E S    0 .3 1 5 2 6 4  H z  
 A Q   1 .5 8 6 0 2 1 2  s e c  
 R G    1 4 4  
 D W    4 8 .4 0 0  u s e c  
 D E    6 .5 0  u s e c  
 T E    2 9 9 .7  K  
 D 1  1 .0 0 0 0 0 0 0 0  s e c  
 T D 0    1 
 = = = = = = = =  C H A N N E L f1  = = = = = = = =  
 N U C 1    1 H  
 P 1    1 0 . 6 5  u s e c  
 P L 1    0.00 dB 
 P L 1 W    2 3 .5 3 6 3 7 5 0 5  W  
 S F O 1   5 0 0 .1 3 3 0 8 8 5  M H z  
 F 2  -  P r o c e s s ing  p a r a m e t e rs  
 S I    3 2 7 6 8  
 S F  5 0 0 .1 3 0 0 0 4 1  M H z  
 W D W    E M  
 S S B    0  
 L B    0 .3 0  H z  
 G B    0 
 P C    1 .0 0  
 
 
 
 
 
14 1 3 1 2  1 1  1 0  9   8  7  6  5  4  3 2  1  0  ppm 
  5.
03
 
  0.
76
 
0.
98
 
1.
00
 
5.
62
 
2.
41
 
13
.
53
 
6.
96
 
  42
.
15
 
 1.
5
3    
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S10. 
 
 
 
Current Data Parameters  
NAME Feb10−2014 
EXPNO 9 
PROCNO 1 
F2 − Acquisition Parameters 
Date_ 20140210 
Time 18.17 
INSTRUM spect 
PROBHD 5 mm PABBO BB− 
PULPROG zg30 
TD  32768 
SOLVENT DMSO 
NS  32 
DS  2 
SWH  10330.578 Hz 
FIDRES 0.315264 Hz 
AQ  1.5860212 sec 
RG  203 
DW  48.400 usec 
DE  6.50 usec 
TE  296.5 K 
D1  1.00000000 sec 
TD0  1 
 
======== CHANNEL f1 ======== 
NUC1 1H 
P1  10.65 usec 
PL1  0.00 dB 
PL1W 23.53637505 W 
SFO1 500.1330885 MHz 
F2 − Processing parameters 
SI  32768 
SF  500.1300000 MHz 
WDW  EM 
SSB  0 
LB  0.30 Hz 
GB  0 
PC  1.00 
 
 
 
 
 
 
14 13 12 11 10 9 8 7 6 5 4 3 2 1 0  ppm 
 
. 0 0 1 . 0 3 1.
09
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MASS SPECTROSCOPY 
COMPOUND   S1 
 
 
 
COMPOUND S2 
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COMPOUND  S3 
 
 
COMPOUND  S4 
 
  
CHAPTER - VII                                                             SPECTRAL DATA 
 
Department of Pharmaceutical Chemistry, MMC, Madurai. 95 
 
 
COMPOUND  S5 
 
 
COMPOUND   S6 
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COMPOUND  S7 
 
 
COMPOUND  S8 
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COMPOUND  S9 
 
 
COMPOUND  S10 
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BIOLOGICAL EVALUATION 
 
 ANTI OXIDANT ACTIVITY11,12 
Principle: 
 The free radical scavenging activity of synthetic drug against hydrogen peroxide was 
determined by using the method of  Ruch et al 1989[70] the principle was based on the 
capacity drug to decompose the hydrogen peroxide to water. 
Reagent: 
  1] 6% hydrogen peroxide diluted with water in ratio of 1:10 
             2] 0.1 m phosphate buffer PH[7.4] 
Procedure: 
 Synthetic compound was dissolved in ethanol to get a stock solution containing 
1mg/1ml various quantities of the stock solution were added to 3.8 ml of 0.1 m phosphate 
buffer solution was added and the absorbance was measured at 230 nm after 10 minutes. The 
reaction without sample was used as blank ascorbic acid was used as standard .the percentage 
inhibition of hydrogen peroxide was calculated using the formula. 
 =    [   A control-    A sample]  x100 
                              A control 
 The concentration of compound to produce 50% inhibition  was found using linear 
regression analysis and results obtained are presented. 
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INVITRO ANTICANCER48 
METHODOLOGY 
Cell line 
The human cervical cancer cell line (HeLa) was obtained from National Centre for Cell Science 
(NCCS), Pune and grown in Eagles Minimum Essential Medium containing 10% fetal bovine serum 
(FBS). The cells were maintained at 370C, 5% CO2, 95% air and 100% relative humidity. Maintenance 
cultures were passaged weekly, and the culture medium was changed twice a week. 
Cell treatment procedure 
 The monolayer cells were detached with trypsin-ethylenediaminetetraacetic acid (EDTA) to 
make single cell suspensions and viable cells were counted using a hemocytometer and diluted with 
medium containing 5% FBS to give final density of 1x105 cells/ml. One hundred microlitres per well of 
cell suspension were seeded into 96-well plates at plating density of 10,000 cells/well and incubated to 
allow for cell attachment at 370C, 5% CO2, 95% air and 100% relative humidity. After 24 h the cells 
were treated with serial concentrations of the test samples. They were initially dissolved in neat 
dimethylsulfoxide (DMSO) and an aliquot of the sample solution was diluted to twice the desired final 
maximum test concentration with serum free medium. Additional four serial dilutions were made to 
provide a total of fivesample concentrations. Aliquots of 100 µl of these different sample dilutions were 
added to the appropriate wells already containing 100 µl of medium, resulting in the required final 
sample concentrations. Following sample addition, the plates were incubated for an additional 48 h at 
370C, 5% CO2, 95% air and 100% relative humidity. The medium containing without samples were 
served as control and triplicate was maintained for all concentrations.  
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MTT assay 
3-[4,5-dimethylthiazol-2-yl]2,5-diphenyltetrazolium bromide (MTT) is a yellow water soluble 
tetrazolium salt. A mitochondrial enzyme in living cells, succinate-dehydrogenase, cleaves the 
tetrazolium ring, converting the MTT to an insoluble purple formazan. Therefore,the amount of 
formazan produced is directly proportional to the number of viable cells. 
 After 48h of incubation, 15µl of MTT (5mg/ml) in phosphate buffered saline (PBS) 
was added to each well and incubated at 370C for 4h. The medium with MTT was then flicked off and 
the formed formazan crystals were solubilized in 100µl of DMSO and then measured the absorbance at 
570 nm using micro plate reader. The percentage cell viability was then calculated with respect to 
control as follows 
% Cell viability = [A] Test / [A]control x 100 
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IN VITRO- ANTIBACTERIAL ACTIVITY22 
TEST CONCENTRATION: 
• 100µg/ml 
• 200µg/ml 
ORGANISM USED: 
• Staphylococcus  aureas 
• Salmonella typhi 
SOLVENT USED:          
• DMSO 
STANDARD DRUG: 
• Amikacin 
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MEDIA PREPARATION21 
MULLER- HINTON AGAR MEDIUM: 
INGREDIENTS: 
                                    Beef infusion                -  300ml 
                                    Casein Hydrolysate     -    17.5g 
                                     Starch                           -    1.5g 
                                     Agar                              -    10g 
                                    Distilled water             -    1litre 
PROCEDURE: 
                 Emulsify the starch in a small amount of cold water, pour into the beef infusion and 
add the casein hydrolysate and the agar. Make up the volume to 1litre with distilled water. 
Dissolve the constituents by heating gently at 100°C with agitation. Filter if necessary. Adjust 
the pH to 7.4.Dispense in screw-capped bottles and sterilized by autoclaving at 121°C for 
20minutes and pour plates.  
PREPARATION OF ANTIBACTERIAL SOLUTION: 
 All the test compound were dissolved in dimethyl sulfoxide and taken at two 
concentration for testing antibacterial activity. The compounds were diffuse into the medium 
produced a concentration gradient. After the incubation period, the zone of inhibition were 
measured in mm. 
 EXPERIMENTAL PROCEDURE: 
  The plates were inoculated by dipping a sterile swab into inoculums. The inoculation 
was dried at room temperature in aseptic condition. Ditch the bore in plate, to this bore add 
prepared antibacterial solution. These plates were placed in an incubator at 37°C within a few 
minutes of preparation. After 48 hours of incubation the diameter of zone of inhibition was 
measured and reading observed in millimeter. 
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RESULTS AND DISCUSSION 
LIPINSKIS RULE BY CHEMDOODLE 
Table.No:1 
Code M.W M.R 
cm3/mol 
H bond 
acceptor 
H bond 
donor 
Logp No.of.criteria 
Rule <500 <150 <10 <5 <5 Atleast 3 
S1 245.2 70.3 4 1 1.9 ALL 
S2 321.3 94.8 4 1 3.5 ALL 
S3 355.8 99.8 4 1 4.1 ALL 
S4 364.4 109.1 5 1 4.1 ALL 
S5 351.3 101.3 5 1 3.8 ALL 
S6 328.3 100.9 3 0 4.3 ALL 
S7 404.4 123.4 2 1 6.4 ALL 
S8 277.2 80.7 2 0 1.2 ALL 
S9 230.2 66.7 3 0 2.4 ALL 
S1O 215.2 66.7 2 2 3.5 ALL 
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PHYSICAL DATA 
TABLE-2 
CODE MOLECULAR 
FORMULA 
MOLECULAR 
WEIGHT 
I.U.P.A.C NAME 
S1 C13H15N3O2 245.277 1-(Piperazine-1-ylmethyl)-1H-indole 2,3 dione 
S2 C19H19N3O2 321.373 1-(phenyl (piperazine-1-yl 
methyl)-1H –indole 2,3 dione 
S3 C19H18N3O2CL 355.818 1-(4-chlorophenyl)(piperazine-1-yl methyl)-1H- indole2,3 dione 
S4 C21H24N4O2 364.440 1-[(4-dimethylaminopiperazine-yl-methyl)-1H-indole 2,3 dione 
S5 C20H21N303 351.399 1-[(4methoxyohenyl)(piperazine-yl methyl)-1H- indole2,3 dione 
S6 C21H16N2O2 328.3639 1-[(diphenylamino) methyl]-1H indole 2,3 dione 
S7 C27H20N2O2 404.459 1-[diphenylamino,phenyl]-yl 
methyl)-1H-indole 2,3 dione 
S8 C16H11N3O2 277.277 1-(1H-benzimidazole-yl methyl)-1H-indole 2,3 dione 
S9 C13H14N2O2 230.262 1-(pyrrolidine-1-yl methyl)-1H-indole-2,3 dione 
S10 C12H15N3 201.267 3-(piperazine-1-yl methyl)-1H-indole 
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PHYSICAL DATAS 
TABLE-3 
Compounds Nature of Crystals 
Melting Point % Yield Soluble in 
S1 Pale orange solid 197 80 DMSO 
S2 Orange solid 212 72 DMSO 
S3 Pale yellow solid 204 75 DMSO 
S4 Brick red solid 220 82 DMSO 
S5 Red solid 206 76 DMSO 
S6 Dark red soid 216 82 DMSO 
S7 Red solid 230 74 DMSO 
S8 Brick red solid 202 80 DMSO 
S9 Black colour solid 210 75 DMSO 
S10 White solid 180 70 DMSO 
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THIN LAYER CHROMOTOGRAPHY 
TABLE-4 
 
S.NO 
 
COMPOUND 
 
RF-VALUE 
1 S1 0.37 
2 S2 0.34 
3 S3 0.41 
4 S4 0.42 
5 S5 0.39 
6  S6 0.44 
7 S7 0.46 
8 S8 0.43 
9 S9 0.38 
10 S10 0.47 
 
                               SOLVENT SYSTEM:      BENZENE: METHANOL 
                            RATIO:                                       9:1 
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ELEMENTAL COMPOSITION 
TABLE-5 
Compounds                          Elemental Composition in Percentage 
       C H         N O Cl 
 
S1 
 
63.66 
 
 
6.16 
 
17.13 
 
13.05 
 
 
S2 
 
71 
 
 
5.96 
 
13 
 
9 
 
 
S3 
 
64.13 
 
 
5.10 
 
11.81 
 
8.99 
 
9.96 
 
S4 
 
69.21 
 
 
6.66 
 
15.37 
 
8.78 
 
 
S5 
 
68.36 
 
 
6.02 
 
11.96 
 
13.66 
 
 
S6 
 
76.81 
 
 
4.91 
 
8.53 
 
9.74 
 
 
S7 
 
80.18 
 
 
4.98 
 
6.93 
 
7.91 
 
 
S8 
 
69.31 
 
 
4.00 
 
15.15 
 
11.54 
 
 
S9 
 
67.81 
 
 
6.13 
 
12.17 
 
13.90 
 
 
S10 
 
71.61 
 
 
7.51 
 
20.88 
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IR SPECTROSCOPY DATAS 
TABLE-6 
 
COMPOUND 
 
FUNCTIONAL GROUP 
 
FREQUENCIES   
CM-1 
 
 
 
S1 
         C=O [str] 
         C-N [str] 
         C=C [str] 
         N-H [str] 
     CH Stretching in benzene 
1739 
1350 
1612 
3192 
2956 
 
 
S2 
           C=O[str] 
           C-N [str] 
           C=C [str] 
           N-H [str] 
         CH stretching in benzene 
1726 
1330 
1620 
3192 
3037 
 
. 
 
S3 
           C=O [str] 
           C-N [str] 
           N-H [str] 
           C=C [str] 
          C-CL [str] 
         CH stretching in benzene 
1705 
1332 
3346 
1612 
802 
2960 
 
 
 
S4 
           C=O [str] 
           C-N [str] 
           N-H [str] 
           C=C [str] 
           C-C  [str] 
1728 
1330 
3192 
1616 
1095 
 
 
 
S5 
            C=O [str] 
            C-N  [str] 
            C=C [str] 
            N-H  [str] 
            C-OCH3 [str] 
1726 
1330 
1616 
1201 
1095 
 
 
 
CHAPTER -IX                                                               RESULTS AND DISCUSSION 
 
Department of Pharmaceutical Chemistry, MMC, Madurai. 109 
 
 
 
IR SPECTROSCOPY DATAS 
TABLE-7 
 
            
COMPOUND 
 
      FUNCTIONAL 
GROUP 
 
FREQUENCIES   
CM-1 
S6 
C=O [str] 
C-N [str] 
C=C [str] 
N-H [str] 
CH Stretching in benzene 
1728 
1188 
1614 
1330 
2960 
S7 
C=O[str] 
C-N [str] 
C=C [str] 
C - C[str] 
CH stretching in benzene 
1705 
1201 
1693 
771 
2930 
S8 
C=O [str] 
C-N [str] 
C=N [str] 
C-C [str] 
CH stretching in benzene 
1726 
1330 
1614 
1201 
2920 
S9 
C=O [str] 
C-N [str] 
C=C [str] 
C-C  [str] 
CH stretching in benzene 
1712 
1332 
1612 
1192 
2960 
S10 
C-N  [str] 
C-C [str] 
N-H  [str] 
CH stretching in benzene 
1346 
1168 
3408 
2958 
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NMR SPECTROSCOPY DATAS 
TABLE-8 
CODE TYPES OF PROTON 
OBSERVED  
VALUE 
In PPM 
S1 
m 4H in Ar H 
s 2H in CH2 
s 1H in NH 
8.1 
3.3 
2.7 
S2 m 4H in Ar H 
s 1H in NH 
7.5 
2.3 
S3 
m 4H in Ar H 
s  1H in NH 
s 1N in CH 
7.3 
2.6 
3.3 
S4 
m 8H in Ar H 
d 6H in CH3 
s 1H in NH 
7.3 
6.5 
3.3 
S5 
m 8H in Ar H 
s 3H in  OCH3 
s 1H in  NH 
7.8 
3.4 
2.6 
S6 m 14H in Ar H 
s 2H in CH2 
7.2 
3.8 
S7 m 19H in Ar H 
s 1H in CH 
7.5 
3.3 
S8 m 9H in Ar H d 2H in CH2 
7.2 
3.8 
S9 m 10H in CH2 
m 4H in Ar H 
3.9 
7.7 
S10 
m 4H in Ar H 
s  2H in NH 
s  2H in CH2 
8.1 
4.5 
3.8 
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MASS SPECTROSCOPY DATAS 
                                                            TABLE-9 
 
SL. NO. COMPOUND 
OBSERVED 
PEAK 
1 S1 245 
2 S2 321 
3 S3 355 
4 S4 364 
5 S5 351 
6 S6 328 
7 S7 404 
8 S8 277 
9 S9 230 
10 S10 201 
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ANTI BACTERIAL ACTIVITY 
[ZONE OF INHIBITION AGAINST MICRO ORGANISM] 
TABLE-10 
 
COMPOUND 
 
STAPHYLOCOCCUS 
AUREAS 
SALMONELLA 
TYPHI 
100µm 200µm 100µm 200µm 
S1 19mm 19mm 11mm 13mm 
S2 12mm 18mm 17mm 22mm 
S3 10mm 15mm 13mm 17mm 
S4 14mm 21mm 15mm 21mm 
S5 14mm 19mm 17mm 23mm 
S6 13mm 15mm 12mm 14mm 
S7 16mm 22mm 18mm 25mm 
S8 14mm 19mm 17mm 24mm 
S9 18mm 19mm 17mm 19mm 
S10 16mm 23mm 14mm 21mm 
STANDARD 19mm 20mm 17mm 18mm 
CONTROL R R R R 
 
  Standard –  Amikacin 
  Control    -   DMSO 
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ANTI OXIDANT PROPERTIES 
TABLE-11 
 
 
                       STD:  ASCORBIC ACID 
                                   *Mean 3value ±SEM 
 
 
COMPOUNDS/ 
CONCENTRATI
ON 
                % INHIBITION* 
100µg/ml 200µg/ml 300µg/ml 
           S1 72.6±0.53 76.4±0.2 69±0.0.28 
 
          S2 70.8±0.46 74.3±0.42 76.7±0.31 
 
          S3 56.1±0.14 59.8±0.26 64.3±0.29 
 
          S4 76.0±0.07 78.7±0.16 79.8±0.24 
 
          S5 75.1±0.13 76.8±0.22 78.7±0.21 
 
          S6 64.2±0.22 71.2±0.24 73.9±0.13 
 
          S7 72.9±0.34 76.8±0.25 79.7±0.22 
 
          S8 75.5±0.39 78.0±0.11 83.71±0.3 
 
          S9 57.6±0.31 61.7±0.35 64.8±0.16 
 
         S10 55.6±0.20 57.9±0.23 59.8±0.27 
 
         STD 83.1±0.20 85.2±0.17 87.5±0.23 
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CYTO TOXICITY STUDIES (MTT ASSAY) 
TABLE-12 
COMPOUND CONCENTRATIO
N 
        (µg/ml) 
ABSORBANC
E 
%CELL 
VIABILITY 
S1 
0.1 
1 
10 
50 
100 
control 
0.47 
0.45 
0.43 
0.42 
0.40 
0.47 
101.1 
97.3 
93.2 
83.4 
85.4 
101.1 
S3 
0.1 
1 
10 
50 
100 
Control 
0.46 
0.45 
0.44 
0.42 
0.40 
0.47 
99.7 
97.0 
95.2 
90.9 
85.4 
101.1 
S6 
0.1 
1 
10 
50 
100 
Control 
0.47 
0.46 
0.46 
0.44 
0.38 
0.47 
100.8 
97.9 
98.5 
94.5 
81.3 
101.1 
S8 
0.1 
1 
10 
50 
100 
Control 
0.47 
0.46 
0.45 
0.41 
0.31 
0.47 
100.0 
99.0 
95.8 
86.6 
67.7 
101.1 
S9 
0.1 
1 
10 
50 
100 
control 
0.46 
0.46 
0.45 
0.45 
0.44 
0.47 
99.6 
99.3 
97.2 
96.4 
93.9 
101.1 
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Results and Discussion 
 The molecular design of synthesized compound were done by using different software. 
 The lipinskin rule was predicted for all synthesized compound using CHEMDOODLE. 
It shows no vialation in basic properties .The results were shown in Table -1 
 The molecular formula,molecular weight and I.U.P.A.C name were predicted and 
shown in Table-2 
 The pecentage yield,  melting point,  solubility and appearance of the compound are 
determined and shown in Table-3 
 The purity of the compounds were checked by TLC and Rf value were calculated. The 
results were shown in Table-4 
 Elemental compostion were found and calculated in percentage and results obtained 
were shown in Table-5 
 The structure of the synthesized compounds were confirmed by IR spectra NMR 
spectra and Mass spectra. 
 IRspectra interpert value shown in Table -6,7 
 NMR specctra interpert value shown in Table -8 
 Mass spectra results were shown in Table-9 
 All synthesized compounds were screened for their invitro antimicrobial, antioxidant 
and anti cancer activity 
 The antibacterial activity was performed against staphylococcus aureas,salmonella 
typhi. The zone of inhibition was performed by cup-plate method and results were 
measured in milimeter shown in Table-10 
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 The graphical representation compound were shown and compared with the standard 
amikacin 
 All synthesized compound were tested for invitro anti oxidant activity by hydrogen 
peroxide method in different concentration and compared with the standard ascorbic 
acid. The result are shown in Table-11 
 All of the newly obtained compound were tested for invitro anti cancer activity by 
MTT Assay method in different concentration and compared with the standard 
diclofenac. The results are shown in Table-12 
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SUMMARY AND CONCLUSION 
 The present study describes the synthesis of novel series of 1-substituted isatin 
derivatives by mannich reaction this methodology offers the wide advantages of  the existing 
procedure available for the synthesis of isatin derivatives. 
 The purity of the synthesised compounds were analysed by thin layer chromatography. 
The structure of the synthesised compound has been elucidated by infra red ,nuclear magnetic 
resonance,mass spectroscopy. 
 The compound S5,S7,S8 shown potent antibacterial activity against salmonella typh.i  
the compound S7,S10 shown best anti bacterial activity against staphylococcus aureas both are 
compared to standard amikacin. 
 The new data might be helpful in the future development of isatin analogue as novel 
broad spectrum antibacterial agent. 
 The compound S4,S7,S8 Shown good anti oxidant properties it has identified by the 
assay of hydrogen peroxide method. 
 The anti cancer activity of the synthesised compounds were screened by using MTT 
assay in cervical cancer cell line, from this result compound S8 having 67%cell viability. so the 
compound S8 shown significantly less cytotoxic activity. 
 Ultimately i would like to deliver the compound S8 (1-[1H-benzimidazole-1-yl 
methyl]-1H-indole-2, 3 –dione)having three activities like ant oxidant activity, anti bacterial 
activity and cytotoxic activicty, in future compound S8 should be modified by chemical 
reaction when it gives potent and effective molecule. 
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